EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase

Adrian Martinez de la Torre, Andreas Bech Clausen, Andrea M Burden, Stefan Weiler iD

Drug Safety · 2025

DOI: 10.1007/s40264-024-01490-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Safety, 2025. Verfasst von Adrian Martinez de la Torre und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technol…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Adverse Drug Reaction Reporting Systems, Fractures, Bone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Fonden, Nordea-fonden, Swiss Federal Institute of Technology Zurich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The Janus kinase (JAK) inhibitors are treatment options for autoimmune diseases. Numerous safety concerns have been raised. The European Medicines Agency updated the product information of tofacitinib to include the risk of fractures-but not for other JAK inhibitors. We conducted a global pharmacovigilance analysis of previously investigated JAK inhibitors to investigate a potential class effect. METHODS: Individual case safety reports (ICSRs) for all licensed JAK inhibitors were identified from the global WHO pharmacovigilance database. The primary outcome of interest was a bone fracture. Disproportionality analyses using reporting odds ratios (RORs) were conducted. RESULTS: We identified 122,037 ICSRs for tofacitinib, 27,786 ICSRs for upadacitinib, 14,616 ICSRs for baricitinib, 830 for filgotinib, and 350 for abrocitinib. Among the ICSRs, we identified 2198 (1.8%), 634 (2.3%), and 144 (1.0%) reports, where a bone fracture was reported for tofacitinib, upadacitinib, and baricitinib, respectively. Few reports were available for the newest drugs filgotinib (10) and abrocitinib (1). JAK inhibitors were associated with increased reporting for fracture: tofacitinib (ROR 3.34, 95% confidence interval [CI] 3.20-3.48), upadacitinib (ROR 4.23, 95% CI 3.80-4.48), baricitinib (ROR 1.80, 95% CI 1.52-2.11) and filgotinib (ROR 2.24, 95% CI 1.11-3.94). Patients with bone fractures were more often female, older and had a higher number of co-reported medications. They were more likely to use glucocorticoids, opioids, and bisphosphonates. CONCLUSION: The results from this pharmacovigilance analysis, based on a spontaneous reporting database associated with inherent limitations, suggest a potential risk of fractures with JAK inhibitors, indicating that a class effect cannot be ruled out.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsAdverse Drug Reaction Reporting SystemsFractures, BoneHumansPharmacovigilanceFemaleWorld Health OrganizationMalePiperidinesMiddle AgedPyrimidinesAdultAgedDatabases, FactualAzetidinesPurines

Substanzen

Janus Kinase InhibitorsPiperidinesPyrimidinestofacitinibAzetidinesPurines

Autor:innen und Institutionen

  • Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich ETH Zürich, HCI H 407 Vladimir-Prelog-Weg 1-5/10, 8093, Zur…
  • Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Institute of Primary Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland. stefan.weiler@pharma.ethz.ch.

ORCID-Profile: Stefan Weiler

Förderung

  • Novo Nordisk Fonden
  • Nordea-fonden
  • Swiss Federal Institute of Technology Zurich

Zitieren

APA

Martinez de la Torre, A., Clausen, A. B., Burden, A. M., & Weiler, S. (2025). Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase. Drug Safety. https://doi.org/10.1007/s40264-024-01490-w

Vancouver

Martinez de la Torre A, Clausen AB, Burden AM, Weiler S. Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase. Drug Safety. 2025. doi:10.1007/s40264-024-01490-w

BibTeX
@article{MartinezdelaTorre2025,
  author = {Martinez de la Torre, Adrian and Clausen, Andreas Bech and Burden, Andrea M and Weiler, Stefan},
  title = {Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase},
  journal = {Drug Safety},
  year = {2025},
  doi = {10.1007/s40264-024-01490-w}
}
Kostenlos starten →